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   ABSTRACT 
 
Background: Nearly half of all patients with 
acute myocardial infarction (AMI) have left 
ventricular systolic dysfunction and one-third 
have symptoms of heart failure (HF). In 
patients with AMI the resistin level correlated 
inversely with left ventricular ejection fraction 
(LVEF). Increased levels of high sensitive (hs) 
troponin I are associated with poorer prog-
nosis. This study aimed to determine the 
association between levels of resistin and hs 
troponin I in ST elevation myocardial infarction 
(STEMI) patients with systolic HF. 
Subjects and Method: This was a cross-
sectional study was conducted at Dr. Moewardi 
General Hospital, Surakarta, from April 1 to 
May 31, 2018. A sample of 32 patients who 
admitted which diagnosed with STEMI was 
selected for this study. They were divided into 
two group according to result of LVEF mea-
surement, LVEF < 40% and LVEF ≥ 40%. 
Blood examination and transthoracic echo-car-
diography were performed to all patients. Cor-
relation test using partial and multiple cor-
relation test. To different 2 mean using Mann 
Whitney test. 
Results: Mean of patient age was 59.5 years 
old. Resistin decreased LVEF (r= -0.41; p= 
0.009), and it was statistically significant. Hs 
troponin I decreased LVEF (r= -0.25; p= 
0.081), but it was marginally significant. Resis-
tin level and hs troponin I increased LVEF (r= 
0.47; p= 0.025), and it statistically significant.  
Conclusion: There was an association 
between resistin and hs troponin I level 
together in STEMI patients with systolic HF. 
There was an association of resistin levels in 
STEM I patients with systolic HF. There was no 
association of hs troponin I levels in STEMI 
patients with systolic HF. 
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BACKGROUND 
Nearly half of all patients with acute myo--
cardial infarction (AMI) experience left ven-
tricular (LV) systolic dysfunction and one 
third show symptoms of heart failure (HF). 
Based on ESC/ACCF/AHA, HF can be divi-
ded into 3 types namely HF with dec-reased 
ejection fraction (EF) or systolic HF 
(EF<40%); HF with midrange ejection frac-
tion (EF 40-49%); and HF with good ejection 
fraction (EF ≥ 50%) (Ponikowski et al., 
2016). Research in ACS patients shows that 
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serum resistin levels correlate inversely with 
the left ventricular ejection fraction (LVEF), 
thus showing an increase in resistin related 
to the severity of injury ischemic myocardial 
(Chu et al., 2008). Other studies suggest that 
increased serum resistin in ST elevation 
myocardial infarction (STEMI) pa-tients 
correlates with major adverse cardiac events 
(MACE) (Erer et al., 2014). 
Resistin plays a role in the development 
of atherosclerosis as in studies on smooth 
muscle cell (SMC) and monocytes/ macro-
phages. Resistin plasma levels have been 
shown to increase in inflammatory condi-
tions. The expression of mRNA and resistin 
secretion is triggered by lipopoly saccharide 
(LPS) and TNF-α in leukocytes involved in 
the innate and adaptive immune system. At 
the same time resistin alone increases the 
inflammatory reaction by increasing pro-
inflammatory cytokine production. Resistin 
together with other inflammatory cytokines 
can create changes that support the develop-
ment of atherosclerosis (Kunnari, 2008). Se-
rum resistin levels are associated with white 
blood count (WBC) and hsCRP. Resistin can 
also increase the activation of human endo-
thelial cells by increasing the release of endo-
thelin-1, adhesion cells and matrix metal -
proteinase which all causes proinflammato-
ry activity and causes plaque instability. It 
can be said that resistin may play a role in 
the development of ACS by influencing 
plaque susceptibility through a series of pro-
inflammatory cells and cytokines (Chu et al., 
2008). A meta-analysis data reports that 
resistin levels correlate with cardiovascular 
death especially in high risk individuals 
(Fontana et al., 2015). Inflammatory markers 
such as interleukin (IL)-6, c reactive protein 
(CRP) and tumor necrosis factor-α(TNF-α) 
are independently correlated with cardiovas-
cular events (Gencer et al., 2016). The direct 
effect of resistin to the expression of IL-1β, 
IL-6, IL-8 and TNF-α, compatible with multi 
cytokine resistance pathways associated with 
several risk factors for insulin resistance or 
low grade inflammation and MACE (Men-
zaghi et al., 2017). The direct mechanism of 
resistin to HF was demonstrated in neonatal 
mice with adenovirus-mediated over expres-
sion. In this study resistin resulted in increa-
sed sarcomere organization, cell size and 
protein synthesis in cardiomyocytes, as well 
as expression of atrial natriuretic factors and 
myosin heavy chains. The heart requires a 
high ATP to maintain mechanical function 
continuously, a decrease in ATP affects the 
myocardium which directly affects myo--
cardial contraction and subsequently causes 
HF (Doenst et al., 2013). 
High sensitivity troponin (hsTn) is 
recommended to be the standard of exami--
nation in the emergency department for pa-
tients with chest pain, replacing previous 
cardiac markers such as myoglobin, CKMB 
and troponin. This test is substantially more 
sensitive than the previous test but has low 
specificity for AMI, because it can detect 
myocardial injury from various causes (Mor-
row and Antman, 2009). Increased levels of 
hs Tn I are associated with a worse prognosis 
(Bonaca et al., 2010). In the event of an AMI, 
an increase in hsTn I level will occur, which 
is a unit that inhibits the troponin complex to 
associate with thin filaments, and inhibits 
the actin-myosin interaction of intracellular 
Ca2 +, where changes in the Ca2 + role will 
also result in changes in regulation of myo-
cardial contractility (Layland et al., 2005). 
The purpose of this study was to 
determine the association between resistin 
levels and hs troponin I in ST elevation 
myocardial infarction (STEMI) patients with 
systolic HF. 
 
SUBJECTS AND METHOD 
1. Study Design 
The study was conducted at the Emergency 
Room and Intensive Cardiovascular Care 
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Unit (ICVCU) at Dr. Moewardi General Hos-
pital Surakarta in STEMI patients. This study 
uses a cross sectional design. 
2. Population dan Sample 
A total of 32 patients with STEMI who were 
treated at ICVCU of Dr. Moewardi General 
Hospital, from 1 April to 31 May 2018, was 
selected by consecutive sampling. 
3. Study Variables 
The dependent variable in this study was 
systolic Heart Failure. The independent 
variable in this study is resistin and high 
sensitive troponin I 
4. Study Instruments 
The definition of STEMI patients is in accor-
dance with the recommendations of the Eu-
ropean Society of Cardiology (ESC) / Ame-
rican College of Cardiology Foundation 
(ACCF)/American Heart Association (AHA)/ 
WHO task force (Thygesen et al., 2012). 
Exclusion Criteria: patients with acute aortic 
dissection, severe sepsis, malignancy, im-
muno compromised disorders and patients 
with chronic kidney disease. Systolic heart 
failure is defined as a left ventricular ejection 
fraction (LVEF) <40% by exami-nation of 
the GE Vivid 6 brand echocardio-graphy by 
Simpson’s method. Resistin levels were mea-
sured by the Elisa method by Prodia clinical 
laboratories. Hs troponin I levels were mea-
sured by Elisa's method by clinical labo-
ratory of Dr. Moewardi hospital. 
5. Data Analysis 
Data analysis was performed using the Mann 
Whitney test. 
6. Research Ethic 
The research ethics include inside informed 
consent, identity confidentiality, and ethical 




The study subjects were 32 people with an 
average age of 59.5±9.59 years, divided into 
two groups, namely the group that had a 
LVEF of less than 40% by 15 people (46.9%) 
and the rest were the group that had the 
same LVEF or greater than 40% which was 
17 people (53.1%). 
The mean age of patients with LVEF 
<40% (58.47± 8.75) was not significantly dif-
ferent from patients with LVEF ≥40% (60.41 
±10.46) with p= 0.576. There were no signifi-
cant differrences in the onset of chest pain, 
urea, creatinine, total cholesterol, LDL cho-
lesterol, HDL cholesterol, triglycerides and 
HbA1c in patients with LVEF <40% and 
LVEF ≥ 40%. 
The results of homogeneity testing of 
characteristic variables that are quantitative 
found that all of these characteristic variables 
are homogeneous. Testing the relationship of 
resistin and hs troponin I to the LVEF that 
shows systolic HF is done by correlation ana-
lysis, both partial correlation and a multiple 
correlation. Description and Test Results 
Homogeneity of quantitative varia-bles of 
demographic and clinical characteris-tics in 
this study is in Table 3. 
Resistin was negatively correlated with 
LVEF (r= -0.41; p= 0.009), and it was sta-
tistically significant. This means, if the 
resistin level is high, then there is a tendency 
for a significant decrease in LVEF and vice 
versa if the resistin is low then the LVEF will 
increase significantly. Hs troponin I was 
negatively correlated with LVEF (r= -0.25; 
p= 0.081), and it was marginally significant. 
This means, if the hs troponin I level is high 
or low there is no tendency to significantly 
increase or decrease LVEF. Resistin level and 
hs troponin I positively correlated with LVEF 
(r= 0.47; p= 0.025), and it was statistically 
significant. This means, if the levels of resis--
tin and hs troponin I together are low or high 
then there will be a tendency for LVEF to 
increase or decrease significantly. 
Table 3 showed the difference of 2 
mean test of resistin and Hs troponin in 
LVEF <40% and LVEF ≥40%. Mean resistin 
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level in LVEF <40% (Mean= 27.81; SD= 
16.99) was higher than LVEF ≥40% (Mean= 
9.38; SD= 5.44), and it was statistically 
significant (p= 0.001). Hs Troponin I in 
LVEF <40% (Mean= 8833.25; SD= 9260.12) 
was higher than LVEF ≥40% (Mean= 
4923.58; SD= 7601.43), but it was statistical-
ly non-significant (p= 0142). Table 3 showed 
the difference of 2 mean test of resistin and 
Hs troponin in LVEF <40% and LVEF ≥ 
40%. Mean resistin level in LVEF <40% 
(Mean= 27.81; SD= 16.99) was higher than 
LVEF ≥40% (Mean= 9.38; SD= 5.44), and it 
was statistically significant (p= 0.001). Hs 
Troponin I in LVEF <40% (Mean= 8833.25; 
SD= 9260.12) was higher than LVEF ≥40% 
(Mean= 4923.58; SD= 7601.43), but it was 
statistically non-significant (p= 0142).
 
Table 1. Comparison of Variable Characteristics of Left Ventricular Ejection 
Faction Group <40% and Group ≥ 40%.  
Variable 
LVEF< 40% LVEF ≥ 40% OR p 
N % N % 
Gender 
a. Male 11 73.3 13 76.5 
0.04 0.838 
b. Female  4 26.7 4 23.4 
STEMI type 
a. Anteroseptal 2 13.3 2 11.8 
6.69 0.351 
b. Anterior 2 13.3 5 29.4 
c. Anterior extensive 5 33.3 3 17.6 
d. Inferior 3 20.0 3 17.6 
e. Inferoposterior 1 6.7 1 5.9 
f. Inferior RV 0 0.0 3 17.6 
g. Inferoposterior RV 2 13.3 0 0 
Early Killip Class 
a. I 8 53.3 12 70.6 
1.08 0.583 b. II 6 40.0 4 23.5 
c. IV 1 6.7 1 5.9 
DM 
a. DM 6 40.0 6 35.3 
0.08 0.784 
b. Non DM 9 60.0 11 64.7 
History of Hypertension 
a. Hypertension 10 66.7 6 35.3 
3.14 0.077 
b. No hypertension 5 33.3 11 64.7 
Smoker status 
a. Smoker  5 33.3 10 58.8 
2.08 0.149 
b. Non smoker 10 66.7 7 41.2 
History of Dyslipidemia 
a. Yes 5 33.3 4 23.5 
0.38 0.538 
b. No Dyslipidemia 10 66.7 13 76.5 
Worsening Killip 
a. Yes 3 20.0 2 11.8 
0.41 0.522 
b. No  9 80.0 15 88.2 
Death Event 
a. Yes 4 26.7 2 11.8 
1.16 0.281 
b. No  11 73.3 15 88.2 
Arrhythmias 
a. Yes 6 40.0 3 17.6 
1.97 0.160 
b. No 9 60.0 14 82.4 
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Table 2. Results of Correlation Analysis of Resistin and Hs Troponin I Variables 
with Left Ventricular Ejection Fraction 
Independent Variables r p 
Resistin  -0.41 0.009 
Hs Troponin I  -0.25 0.081 
Resistin and Hs Troponin I  0.47 0.025 
 
Table 3. Difference 2 Mean Test of Resistin and Hs Troponin Variable in LVEF 
<40% and LVEF ≥ 40% 
Variable 
LVEF <40 % (n=15) LVEF≥ 40% (n= 17) 
p 
Mean SD Mean SD 
Resistin 27.81 16.99 9.38 5.44 0.001 
Hs Troponin I 8833.25 9260.12 4923.58 7601.43 0.142 
 
Tabel 4. Results of Correlation Analysis of Sample Characteristics on Resistin and 
Hs Troponin I  
Independent Variables 
Resistin Hs Troponin I 
r  p r p 
Gender  0.01 0.991 -0.24 0.810 
Smoker status 1.89 0.068 0.38 0.708 
History of hypertension 1.68 0.104 0.07 0.945 
DM -1.05 0.303 0.92 0.385 
Azotemia 1.52 0.139 0.88 0.385 
Dyslipidemia 0.47 0.646 1.49 0.147 
Early Killip Class 0.17 0.848 6.15 0.006 
STEMI type 2.79 0.032 0.78 0.594 
Arrhythmia Events 0.80 0.433 -0.20 0.844 
Death Events 3.35 0.002 1.24 0.225 



















Figure 1. ROC Analysis of Resistin for Systolic Heart Failure 
 
AUC : 0.91 
Sensitivity  : 86.7% 
Specificity : 82.4% 
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The ROC curve generated from the 
resistin variable for the identification of 
systolic HF resulted in an Area under Curve 
(AUC) value of 0.914 or included in the 
excellent category. It can be interpreted 
that the resistin variable identifies very well 
the incidence of systolic HF based on the 
LVEF variable benchmarks. Based on the 
ROC curve, the Cut of Point value of the 
resistin variable is 11.74 ng/mL with a cut 
of point of the resistin variable of 11.74 
ng/mL, the systolic heart failure event can 
be identified from the resistin variable 
having a sensitivity level of 86.7% with a 
specificity level of 82.4% and an accuracy 
rate of 84.4%. 
Meanwhile the ROC curve generated 
from the hs troponin I variable for iden-
tification of systolic HF resulted in an Area 
under Curve (AUC) value of 0.66 or 
included in the weak category. It can be 
interpreted that hs troponin I variable is 
weak in identifying systolic HF based on 
the LVEF variable benchmark. Based on the 
ROC curve, the Cut of Point value of the Hs 
troponin I variable is 5,124.50 ng/L. With 
the cut of point of the Hs troponin I vari-
able of 5,124.50 ng/L, the systolic heart 
failure can be identified from the Hs tropo-
nin I variable has a sensitivity level of 
60.0% with a specificity level of 76.5% and 



















Figure 2. ROC Analysis of Troponin I against Systolic Heart Failure 
DISCUSSION 
 In this study, HF patients were 
divided into two groups, namely HF 
patients with LVEF <40% categorized as 
systolic HF and HF patients with LVEF 
≥40%. In a large sample study, the 
Immediate Myocardial Metabolic 
Enhancement during Initial Assessment 
and Treatment in Emergency care (IMME-
DIATE) Trial in 2016, stated that there 
were signifi-cant differences in post ACS 
patients with LVEF <40% and had a 1-year 
mortality rate or HF hospitalization higher 
than patients with LVEF> 40% 
(Mukherjeeet al., 2016). The results of this 
study indicate that the level of resistin and 
LVEF has a significant negative correlation 
at a significance level of 5% (p <0.05) with 
a correlation value of r = -0.414. This 
means, if the level of resistin increases then 
AUC : 0.66 
Sensitivity  : 60.0% 
Specificity : 76.5% 
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there is a tendency for a significant de-
crease in LVEF and vice versa if the value of 
resistin is low then the LVEF will expe-
rience a significant increase. There was a 
significant difference in resistin levels in 
LVEF <40% with LVEF ≥40% with p 
<0.001. The results of this study are con-
sistent with previous studies that serum 
resistin levels are inversely correlated with 
LVEF, so that an increase in resistin levels 
correlates with the severity of myocardial 
ischemic in ACS patients (Chu et al., 2008). 
 Hs troponin I decreased LVEF, but it 
was statistically non-significant (r= -0.25; 
p>0.05). In addition, there was no differ--
rence between Hs troponin I levels in LVEF 
<40% or with LVEF ≥ 40% with p= 0.142. 
The possibility of this result could be due to 
Troponin I level had a peak time of around 
12 hours and subsequently decreased, 
where-as patients who come to the emer-
gency room have different onset of STEMI 
event (Maha-jan and Jarolim, 2011). 
Combination of resistin and Hs tropo-
nin I increased LVEF and it was statis-
tically significant (r= 0.47; p <0.05). 
By using the ROC curve method, it 
was found that the level of resistin for the 
identification of systolic HF resulted in an 
Area under Curve (AUC) value of 0.914 or 
included in the excellent category. Based on 
the ROC curve, the cut of point value is 
11.74 ng/mL. With the cut of point level of 
resistin of 11.74 ng/mL, the incidence of 
systolic HF can be identified from the 
resistin level which has a sensitivity level of 
86.7% and a specificity level of 82.4%, and 
an accuracy rate of 84.4%; better when 
compared to Hs troponin I level which has 
a sensitivity level of 60% and specificity of 
76.5%, and an accuracy rate of only 68.7%. 
The results of this study indicate that if 
there are 100 STEMI patients with resistin 
levels >11.74 ng/mL, 91 of them are pre-
dicted to experi-encesystolic HF. 
In this study, resistin levels were 
related to the extent of infarction in STEMI 
patients. These results are consistent with 
research conducted by Zhang et al., that 
increased serum resistin levels are related 
to the severity of coronary heart disease 
(Zhang et al, 2017). The results of this study 
also showed that resistin levels were asso-
ciated with death in STEMI patients (p= 
0.002). This is also consistent with the 
results of other researchers, that resistin 
levels is correlated with MACE events 
where one of them is cardiovascular death 
(Menzaghi et al., 2017; Fontana et al., 2015; 
Erer et al., 2014). 
Based on the results of this study, it 
can conclude that there is a correlation 
between resistin and hs troponin I level in 
STEMI patients with systolic HF. There is a 
correla-tion between resistin levels in 
STEMI suffer-ers with systolic HF. There is 
no correlation between hs troponin level in 
STEMI sufferers with systolic HF. Resistin 
levels have a prog-nostic value for the 
occurrence of systolic HF in STEMI 
patients with better sensitivity, specificity, 
and accuracy than hs troponin I levels. 
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